Literature DB >> 10845562

Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model.

T Okada1, R G Hawley, M Kodaka, H Okuno.   

Abstract

In previous work, we established the B9/BM1 syngeneic murine bone marrow metastasis model. Interleukin (IL)-6-dependent. IL-1-producing B9/BM1 cells, which colonize the vertebral and femoral marrow after i.v. injection, show great similarity in cell surface phenotype to human myeloma cells, especially the expression of 3 adhesion molecules, CD44, VLA-4 and ICAM-1. Here we investigated the function of these adhesion molecules by binding and transendothelial invasion assays using a newly established bone marrow-derived endothelial cell line (BMEC). A combination of monoclonal antibodies against CD44 and VLA-4 significantly inhibited the adherence of B9/BM1 cells to BMEC and anti-CD44 mAb especially blocked B9/BM1 transendothelial invasion of unstimulated BMEC cells. Results of additional experiments, in which the cells were treated with anti-CD44 and hyaluronidase, demonstrated that the interaction of CD44 molecules on B9/BM1 cells with hyaluronan on BMEC cells was a critical factor in both adhesion and transendothelial invasion in this model. However, stimulation of BMEC with TNFalpha resulted in increased invasion by B9/BM1 cells, which was completely suppressed by anti-VCAM-1 mAb, implicating a significant role of this adhesion molecule in this process during inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10845562     DOI: 10.1023/a:1006715504719

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  33 in total

1.  Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements.

Authors:  T Okado; R G Hawley
Journal:  Int J Cancer       Date:  1995-12-11       Impact factor: 7.396

2.  Interaction of very late antigen-4 with VCAM-1 supports transendothelial chemotaxis of monocytes by facilitating lateral migration.

Authors:  C Weber; T A Springer
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

3.  Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells.

Authors:  N Itano; T Sawai; O Miyaishi; K Kimata
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

4.  Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer.

Authors:  K Ropponen; M Tammi; J Parkkinen; M Eskelinen; R Tammi; P Lipponen; U Agren; E Alhava; V M Kosma
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

5.  Functions of domain 1 and 4 of vascular cell adhesion molecule-1 in alpha4 integrin-dependent adhesion under static and flow conditions are differentially regulated.

Authors:  Y Abe; C M Ballantyne; C W Smith
Journal:  J Immunol       Date:  1996-12-01       Impact factor: 5.422

6.  Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate.

Authors:  A C Gao; W Lou; J P Sleeman; J T Isaacs
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

Review 7.  Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

8.  Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition.

Authors:  K Miyake; C B Underhill; J Lesley; P W Kincade
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

9.  Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity.

Authors:  J Sleeman; W Rudy; M Hofmann; J Moll; P Herrlich; H Ponta
Journal:  J Cell Biol       Date:  1996-11       Impact factor: 10.539

10.  CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway.

Authors:  H C DeGrendele; P Estess; L J Picker; M H Siegelman
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

Review 2.  The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 3.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

4.  Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells.

Authors:  Tomoko Okada; Shingo Akikusa; Hiroaki Okuno; Masato Kodaka
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.

Authors:  Yuko Hiruma; Tadashi Honjo; Diane F Jelinek; Jolene J Windle; Jaekyoon Shin; G David Roodman; Noriyoshi Kurihara
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

Review 6.  Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.

Authors:  Nagaraju Anreddy; Lori A Hazlehurst
Journal:  J Cell Biochem       Date:  2016-06-21       Impact factor: 4.429

7.  Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow.

Authors:  P A Koni; S K Joshi; U A Temann; D Olson; L Burkly; R A Flavell
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

8.  Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.

Authors:  E Terpos; M Migkou; D Christoulas; M Gavriatopoulou; E Eleutherakis-Papaiakovou; N Kanellias; M Iakovaki; I Panagiotidis; D C Ziogas; D Fotiou; E Kastritis; M A Dimopoulos
Journal:  Blood Cancer J       Date:  2016-05-27       Impact factor: 11.037

9.  Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.

Authors:  Simone S Riedel; Anja Mottok; Christian Brede; Carina A Bäuerlein; Ana-Laura Jordán Garrote; Miriam Ritz; Katharina Mattenheimer; Andreas Rosenwald; Hermann Einsele; Bjarne Bogen; Andreas Beilhack
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.

Authors:  J Teramachi; R Silbermann; P Yang; W Zhao; K S Mohammad; J Guo; J L Anderson; D Zhou; R Feng; K-Z Myint; N Maertz; J H Beumer; J L Eiseman; J J Windle; X-Q Xie; G D Roodman; N Kurihara
Journal:  Leukemia       Date:  2015-08-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.